Table 2.
Circulatory treatment and postoperative outcome in all patients treated with inotropes
| Placebo n = 77 | Glutamate n = 94 | p-value | |
|---|---|---|---|
| Circulatory treatment | |||
| Inotropes (total) | 100 % | 100 % | |
| Inotropes duration (hours) | 38 ± 46 | 29 ± 30 | 0.14 |
| Number of inotropes | 1.4 ± 0.6 | 1.3 ± 0.6 | 0.45 |
| Adrenaline | 63.6 % | 70.2 % | 0.41 |
| Adrenaline duration (hours)a | 28 ± 49 | 17 ± 25 | 0.049 |
| Adrenaline duration (hours)b | 44 ± 55 | 24 ± 27 | 0.01 |
| Average max dosage μg/kg/minb | 0.028 ± 0.016 | 0.028 ± 0.020 | 0.94 |
| Milrinone | 50.6 % | 39.4 % | 0.16 |
| Milrinone duration (hours)a | 14 ± 25 | 9 ± 19 | 0.14 |
| Milrinone duration (hours)b | 27 ± 30 | 22 ± 25 | 0.44 |
| Average max dosage μg/kg/minb | 0.40 ± 0.14 | 0.36 ± 0.12 | 0.28 |
| Noradrenaline | 71.4 % | 70.2 % | 1.0 |
| Average max dosage μg/kg/mina | 0.084 ± 0.093 | 0.068 ± 0.089 | 0.24 |
| Average max dosage μg/kg/minb | 0.118 ± 0.090 | 0.097 ± 0.092 | 0.20 |
| IABP | 5.2 % | 0 % | 0.04 |
| Postoperative outcome | |||
| Time on ventilator (hours) | 34 ± 95 | 26 ± 74 | 0.54 |
| ICU stay (hours) | 63 ± 98 | 59 ± 78 | 0.79 |
| Severe circulatory failure | 17.5 % | 6.2 % | 0.03 |
| Stroke within 24 h | 2.6 % | 3.2 % | 1.0 |
| Cardiac mortality | 2.6 % | 1.1 % | 0.59 |
| 30 day mortality | 1.3 % | 2.1 % | 1.0 |
| Hospital mortality | 2.6 % | 3.2 % | 1.0 |
IABP intra-aortic balloon pump, ICU intensive care unit
aaverage for all patients treated with inotropes
baverage for patients treated with specific drug